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Results. Coverage and dose homogeneity of the PTV measured by D90 and V95% were similar for both plans although breast
maximum dose was higher in the supine plan (p=0.017). Prone position reduced the percentage of ipsilateral lung receiving
20Gy (V20Gy) from 26.5% to 2.9% (p=0.007), medium lung dose, as well as the percentage of the heart receiving 35Gy heart
(V35Gy) from 3.4% to 1.2% (p=0.038). Overdosage of areas outside breast PTV were also consistently reduced with prone position
(p=0.012). Additionally, average number of segments and monitor units needed were reduced in prone position.
Conclusions. Prone position in large breast women appears to favour normal tissue sparing in breast radiotherapy as compared
to supine position, without diminishing the target coverage.
http://dx.doi.org/10.1016/j.rpor.2013.03.856
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Hypothesis. SBRT with Novalis Exactrac Adaptive Gating Linac (Brainlab®) is a secure, highly accurate and feasible PBI technique
with intrafraction control of breast movement.
Goals. 1. Asses the feasibility of applying SBRTwithGating in patientswith breast cancer of VGPwith and accelerated fractionation
(5 fractions×6Gy) in alternate days. 2. Reduce the PTV margin due to the possibility to quantify the breast movement during the
respiratory cycle (RC) and to irradiate in a selected phase of that cycle. 3. Identify and quantify acute and late toxicity according
to RTOG and CTCAE scales.
Inclusion criteria. Women age ≥60 years, pT1 (<2 cm) after breast conserving surgery, surgical margins ≥2mm, pathological
conﬁrmation of inﬁltrating ductal carcinoma, pN0, ECOG 0-1, luminal subtype.
Methods. •Placement of ﬁducial markers close to the surgical bed, prior to simulation. •CT simulation in supine position with
immobilization device and infrared spheres on the skin, as external ﬁducials. •3D conformal radiation therapy with iPlan Net®
(DVH assessed and approved according to ASTRO recommendations for PBI constraints). •Intrafraction control of PTV motion
with Novalis Exactrac Gating System (quantiﬁcation of breast movement during the RC by the correlation of the internal marker
and the external ﬁducials). •PTV irradiation in the selected gated area of the RC. •Assessed of clinical and toxicity outcomes.
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